Implement follow-up measures for patients treated for vitamin B12 deficiency by scheduling an initial follow-up appointment at 3 months after starting treatment, or earlier if symptoms are severe, or at 1 month if pregnant or breastfeeding NICE CKS.
At each follow-up, ask the patient if their symptoms have improved, worsened, or if they have new symptoms related to vitamin B12 deficiency NICE CKS.
For patients on oral vitamin B12 replacement, check they are taking the correct dosage and consider increasing the dose to the maximum licensed dosage if symptoms persist or worsen NICE NG239.
If symptoms have not improved sufficiently, or if they worsen or new symptoms develop, consider increasing injection frequency, exploring alternative diagnoses, and agree on a reassessment date NICE NG239.
For patients with an irreversible cause of deficiency, continue lifelong intramuscular injections and advise them to return if symptoms recur or worsen NICE CKS, NICE CKS, NICE CKS, NICE NG239.
If the cause of deficiency has been addressed and symptoms have improved or resolved, consider stopping or reducing injection frequency, and advise the patient to return if symptoms reappear or worsen NICE CKS, NICE CKS, NICE CKS, NICE NG239.
Measure serum methylmalonic acid (MMA) or plasma homocysteine if symptoms persist or worsen, to explore ongoing deficiency or alternative diagnoses NICE CKS, NICE CKS, NICE CKS, NICE NG239.